E. Michael Lewiecki, MD, discusses how menopause significantly impacts bone health through increased bone remodeling and loss, while exploring promising new neurokinin-targeted therapies like elinzanetant that may simultaneously treat vasomotor symptoms and provide skeletal benefits, as demonstrated in the OASIS-3 trial's subanalysis showing improved bone mineral density, reduced bone turnover markers, and favorable body composition changes compared with placebo.
